Comentarios sobre el tratamiento de la osteoporosis por corticoides
Messina, Osvaldo Daniel.
Reumatol. clín. (Barc.)
; 20(2): 113-113, Feb. 2024.
Artículo en Español | IBECS (España) | ID: ibc-230148
Documentos relacionados
Potential for biosimilars in rheumatology in Africa.
[Recommendations for the medication of rheumatic diseases in periconceptional period].
Rheumatological patients' knowledge of, beliefs about, and practices in using phytotherapy: an exploratory study.
Rheumatology: What You May Have Missed in 2023.
Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.
Advocating for better trials in rheumatology.
[Standardized management of targeted drugs for rheumatism].
Unpublished clinical trials of common rheumatic diseases.
Discrepancies between clinical and pathological findings seen at renal biopsy in rheumatological diseases.
Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).